Recent Company News

• 08:49 PM ET Oct 10, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:50 PM ET Oct 10, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 12-Oct

• 04:57 PM ET Oct 08, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 02:20 PM ET Oct 08, 2025
  

  FDA approves Regeneron's Libtayo (cemiplimab-rwlc) for the adjuvant treatment of adults with CSCC at high risk of recurrence after surgery and radiation ($588.81, +5.57)

• 08:46 AM ET Oct 06, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 01:02 AM ET Oct 08, 2025
  

  Sanofi's AlphaMedix (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors (€84.84, 0.00)

• 06:44 PM ET Oct 07, 2025
  

  Next ACIP meeting no longer calendared for October 22-23

• 07:03 AM ET Oct 07, 2025
  

  Novavax completes Nuvaxovid EU Marketing Authorization transfer, triggering $25M milestone payment ($9.08, 0.00)

• 10:53 AM ET Oct 06, 2025
  

  StreetAccount Summary - Private company transactions for the week ended 04-Oct